Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2024 | DaraVd in the second-line for lenalidomide-refractory patients with myeloma

Elena Zamagni • 25 Sep 2024
IMS 2024
Multiple Myeloma Antibodies Bortezomib Daratumumab

In this video, Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, briefly discusses the use of daratumumab, bortezomib, and dexamethasone (DaraVd) in the second-line setting for patients with multiple myeloma (MM) who are refractory to lenalidomide. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elena Zamagni

A project to improve the understanding of disease biology and treatment outcomes in myeloma 1:34
A project to improve the understanding of disease biology and treatment outcomes in myeloma
Elena Zamagni • 9 Dec 2024
SRI results from MajesTEC-4: Tec-Len or Tec alone as maintenance therapy in newly diagnosed myeloma 1:39
SRI results from MajesTEC-4: Tec-Len or Tec alone as maintenance therapy in newly diagnosed myeloma
Elena Zamagni • 9 Dec 2024
The future of myeloma: the potential role of MRD-driven therapy de-escalation strategies 0:57
The future of myeloma: the potential role of MRD-driven therapy de-escalation strategies
Elena Zamagni • 9 Dec 2024
Patient selection for selinexor 0:35
Patient selection for selinexor
Elena Zamagni • 24 Oct 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals